Steven Fehrenkamp
Endocrinology, Diabetes & Metabolism · Austin, TXNPI 1376582718
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.2% of the total across 403 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,000 and has fallen 61.7% since, to $766 in 2022.
Across 403 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$935
- AstraZeneca$852
- IBSA Pharma Inc.$662
- AbbVie$510
- Sanofi-aventis U.S. LLC$400
- plus $2K from 30 others
What the payments were for
- Consulting fees$5007%
- Food & beverage$6,06190%
- Education$1001%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 82 | $1,066 |
| Lilly USA, LLC | 69 | $935 |
| AstraZeneca | 36 | $852 |
| IBSA Pharma Inc. | 15 | $662 |
| AbbVie(2 entities) | 33 | $510 |
| Sanofi-aventis U.S. LLC | 25 | $400 |
| Amarin Pharma, Inc. | 14 | $289 |
| Amgen | 20 | $241 |
| Mannkind Corporation | 15 | $198 |
| Boehringer Ingelheim | 12 | $193 |
| Bayer | 5 | $175 |
| Corcept Therapeutics | 8 | $172 |
| Xeris Pharmaceuticals, Inc. | 10 | $160 |
| Clarus Therapeutics Inc. | 9 | $108 |
| Insulet Corporation | 6 | $95 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $84 |
| Radius Health, Inc. | 4 | $71 |
| Zealand Pharma US, Inc. | 3 | $54 |
| Shire North American Group Inc | 3 | $45 |
| Johnson & Johnson | 3 | $42 |
| Tandem Diabetes Care, Inc. | 3 | $40 |
| Kowa Pharmaceuticals America, Inc. | 3 | $37 |
| Abbott | 3 | $35 |
| Acerus Pharmaceuticals Corporation | 2 | $34 |
| Dexcom, Inc. | 2 | $32 |
| Antares Pharma, Inc. | 2 | $24 |
| Amryt Pharma Holdings Ltd | 1 | $20 |
| Gilead | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
| Sun Pharmaceutical Industries Inc. | 1 | $14 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tirosint$500
- Tirosint-SOL$500
- Ozempic$228
- FARXIGA$228
- Kerendia$113
How this compares
$6,720 in reported general payments places this provider in the 60th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Other endocrinology, diabetes & metabolism in Austin
- Thomas BlevinsAustin$904K
- Lindsay HarrisonAustin$103K
- Lance SloanLufkin$1.7M
- Pablo MoraDallas$1.3M
- Robert HoodBeaumont$1.3M
- Eduardo LunaEdinburg$1.3M
- Steve FordanDallas$1.2M
- Rosemarie LajaraPlano$1.2M
- Saleemah FahmiDallas$1.2M
- Julio RosenstockDallas$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.